Clinical AdvancesPrelude has two assets advancing through the clinic with initial results expected to provide an attractive investment opportunity.
Innovative ResearchPrelude's novel PROTAC-targeting SMARCA2 exploits synthetic lethality, which could be promising in the fight against cancer.
Partnership GrowthCollaboration with AbCellera aims to develop antibody-drug conjugates for targeted therapy delivery, which could enhance the treatment's precision and effectiveness.